Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen

Content Provider	Semantic Scholar
Author	Liu, Rujiao Huang, Mingzhu Zhao, Xiaoying Peng, Wei Sun, Si Lu Cao, Jun Ji, Dongmei Wang, Chenchen Guo, Weijian Li, Jin Yin, Jiliang Zhu, Xiaodong
Copyright Year	2015
Abstract	Chemotherapy-induced neutropenia (CIN) reportedly indicated better prognosis for some cancers. We retrospectively analyzed 150 evaluable metastatic gastric cancer (MGC) patients who had received first-line EOF5 (combination regimen of epirubicin, oxaliplatin and 5-day continuous infusion of 5-fluorouracil) treatment. We divided patients into three groups according to the worst grade of CIN: absent group (grade 0), moderate group (grade 1-2) and severe group (grade 3-4). Multivariate analyses of overall survival (OS) proved moderate and severe CIN were important prognostic factors whether regarding CIN as a time-varying covariate (TVC) or not. Compared with absent CIN, hazard ratio (HR) for moderate and severe CIN were 0.31 (95% confidential interval (CI): 0.17-0.55; P < 0.001) and 0.36 (95% CI: 0.20-0.64; P = 0.001) respectively with TVC; and were 0.31 (95% CI: 0.17-0.56; P < 0.001) and 0.34 (95% CI: 0.19-0.61; P < 0.001) respectively without TVC. In progression-free survival (PFS) analyses, moderate and severe CIN showed similar results. In the landmark group (n = 122 patients) analyses with TVC, moderate and severe CIN remained prognostic factors for PFS, while only moderate CIN was prognostic factor for OS. CIN predicted longer OS and PFS in MGC patients treated with first-line EOF5 chemotherapy.
Starting Page	39018
Ending Page	39027
Page Count	10
File Format	PDF HTM / HTML
Alternate Webpage(s)	http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&op=download&page=article&path%5B%5D=5730&path%5B%5D=16778
PubMed reference number	26528696v1
Alternate Webpage(s)	https://doi.org/10.18632/oncotarget.5730
DOI	10.18632/oncotarget.5730
Journal	Oncotarget
Volume Number	6
Language	English
Access Restriction	Open
Subject Keyword	Bayer Corneal Epitheliopathy Grade 0 Evaluable Disease Fluorouracil Forecast of outcome Hazard Ratio Malignant Neoplasms Malignant neoplasm of stomach stage IV Neutropenia Overall Survival Patients Phase I/II Trial Prognostic Factors Progression-Free Survival Stomach Carcinoma oxaliplatin
Content Type	Text
Resource Type	Article